Clinical Trials Browser

Phase 2 × Burkitt Lymphoma × tisagenlecleucel × Clear all

NCT03876769 2026-03-13

CASSIOPEIA

Phase 2 Active not recruiting

Burkitt Lymphoma, Neoplasm, Residual

NCT05460533 2026-02-04

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

Phase 2 Active not recruiting

Burkitt Lymphoma, Recurrence

NCT03610724 2024-06-20

BIANCA

Phase 2 Completed

34 enrolled 19 charts

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02435849 2024-02-13

ELIANA

Phase 2 Completed

80 enrolled 39 charts 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04156659 2023-03-09

Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL

Phase 2 Withdrawn

Burkitt Lymphoma

NCT02228096 2020-11-23

ENSIGN

Phase 2 Completed

75 enrolled 41 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02167360 2017-02-14

Study of Efficacy and Safety of CTL019 in Adult ALL Patients

Phase 2 Withdrawn

Burkitt Lymphoma